STREAMLINED DNA SEQUENCING TO IDENTIFY A TUMOR GENE

Information

  • Research Project
  • 2009452
  • ApplicationId
    2009452
  • Core Project Number
    R43CA069996
  • Full Project Number
    1R43CA069996-01
  • Serial Number
    69996
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/15/1996 - 27 years ago
  • Project End Date
    9/14/1998 - 25 years ago
  • Program Officer Name
  • Budget Start Date
    9/15/1996 - 27 years ago
  • Budget End Date
    9/14/1998 - 25 years ago
  • Fiscal Year
    1996
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/13/1996 - 27 years ago

STREAMLINED DNA SEQUENCING TO IDENTIFY A TUMOR GENE

Ependymomas account for approximately 10% of all brain tumors in children and young adolescents. Cytogenetic and loss of heterozygosity studies of ependymomas have shown frequent alterations of chromosome 22q. These data strongly support a tumor suppressor gene involved in this neoplasia on 22q. However, neither the chromosome 22q nor other genes involved in ependymoma have been identified. We have identified a ependymoma patient who exhibits a constitutional translocation [t(1;22)(p22;q11.2)]. The translocation in 22q11.2 lies between the DiGeorge syndrome and the breakpoint cluster (BCR) regions-an interval estimated to be approximately 4 Mb. We hypothesize that this translocation interrupts an ependymoma tumor suppressor gene in 22q11.2 and that it is a landmark for cloning the gene. Our aim in this proposal is to clone this ependymoma tumor suppressor gene by delimiting the 22q1 1.2 breakpoint to 150 kilobases (Phase I) and performing streamlined high-coverage (more than 90%), low- redundancy (2-2.5X) multiplex DNA sequencing and computer exon identification of this region (Phase II). The isolation of an ependymoma tumor suppressor gene would permit a mechanistic understanding of this tumor, as well as other cancers in which this gene may be involved. The cloning of this gene will have important applications to monitoring, diagnostics, and therapeutics for ependymoma. This proposal also will be an important evaluation of the streamlined large-scale DNA sequencing and exon identification approach to positionally clone genes. POTENTIAL COMMERCIAL APPLICATION: The identification of an ependymoma tumor suppressor gene is expected to have applications in monitoring, diagnostics, and therapeutics, as well as a basic understanding of this cancer. This gene may have an association with prognosis; this would be of great importance since there is no good prognostic marker. This gene may be involved in other cancers which show chromosome 22q alterations. Our streamlined sequencing approach should have applications to positionally cloning other disease genes.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG7
  • Study Section Name
  • Organization Name
    OSCIENT PHARMACEUTICALS CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    WALTHAM
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    024538443
  • Organization District
    UNITED STATES